Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ITK | Q08881 | 2/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | IL6 | P05231 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8234940 | 0.88 | CNR1 (0.40) | ALDH1A1TSHRKDM4EPOLBL3MBTL1 | |
| SCHEMBL89627 | 0.87 | ALDH1A1 (0.44) | ALDH1A1TSHRKDM4EPOLBL3MBTL1 | |
| SCHEMBL8264273 | 0.85 | ALDH1A1 (0.40) | ALDH1A1TSHRKDM4EPOLBL3MBTL1 | |
| SCHEMBL664743 | 0.82 | ALDH1A1 (0.43) | ALDH1A1TSHRKDM4EPOLBL3MBTL1 | |
| SCHEMBL8251206 | 0.81 | ALDH1A1 (0.35) | ALDH1A1TSHRKDM4EPOLBL3MBTL1 | |
| SCHEMBL88767 | 0.80 | ALDH1A1 (0.33) | ALDH1A1TSHRKDM4EPOLBL3MBTL1 | |
| SCHEMBL663467 | 0.80 | ALDH1A1 (0.44) | ALDH1A1TSHRKDM4EPOLBL3MBTL1 | |
| SCHEMBL13490847 | 0.79 | KCNH2 (0.44) | ALDH1A1TSHRKDM4EPOLBL3MBTL1 | |
| SCHEMBL10186702 | 0.78 | ALDH1A1 (0.40) | ALDH1A1TSHRKDM4EPOLBL3MBTL1 | |
| SCHEMBL89319 | 0.77 | ALDH1A1 (0.49) | ALDH1A1TSHRKDM4EPOLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| EP-2420491-A1 | 3 , 5-substitued piperidine compounds as renin inhibitors | Novartis AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | ALDH1A1 38/4885TSHR 1095/4885KDM4E 1650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.